Corrigendum to: MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer: MiR-506 targets CDK4/6-FOXM1 axis (The Journal of Pathology, (2014), 233, 3, (308-318), 10.1002/path.4348);MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

Journal of Pathology

Volumn 233, Issue 3, 2014, Pages 308-318

  Liu, Guoyan ^a,b   Sun, Yan ^a,b   Ji, Ping ^a   Li, Xia ^a,c   Cogdell, David ^a   Yang, Da ^a   Parker Kerrigan, Brittany C ^a   Shmulevich, Ilya ^d   Chen, Kexin ^b   Sood, Anil K ^a   Xue, Fengxia ^b   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

FOXM1; miR 506; ovarian carcinoma; proliferation; senescence

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FORKHEAD TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 506; PROTEIN FOXM1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION;

FOXM1; MIR-506; OVARIAN CARCINOMA; PROLIFERATION; SENESCENCE;

3' UNTRANSLATED REGIONS; BINDING SITES; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MICRORNAS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84902344416     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.5338     Document Type: Erratum

References (37)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Heintz AP, Odicino F, Maisonneuve P, et al., Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (suppl 1): S161-192.
3. Clarke-Pearson DL,. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170-177.
4. Coleman MP, Forman D, Bryant H, et al., Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127-138.
5. Dinh P, Harnett P, Piccart-Gebhart MJ, et al., New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 2008; 67: 103-112.
6. Wan SM, Lv F, Guan T,. Identification of genes and microRNAs involved in ovarian carcinogenesis. Asian Pac J Cancer Prev 2012; 13: 3997-4000.
7. Vaksman O, Stavnes HT, Kaern J, et al., miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011; 15: 1593-1602.
8. Mezzanzanica D, Bagnoli M, De Cecco L, et al., Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 2010; 42: 1262-1272.
9. Zhao Y, Liu H, Li Y, et al., The role of miR-506 in transformed 16HBE cells induced by anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Toxicol Lett 2011; 205: 320-326.
10. Streicher KL, Zhu W, Lehmann KP, et al., A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31: 1558-1570.
11. Tong JL, Zhang CP, Nie F, et al., MicroRNA 506 regulates expression of PPARα in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett 2011; 585: 3560-3568.
12. Yang D, Sun Y, Hu L, et al., Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013; 23: 186-199.
13. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
14. Rupaimoole R, Han HD, Lopez-Berestein G, et al., MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer 2011; 30: 368-370.
15. Ansieau S, Morel AP, Hinkal G, et al., TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010; 29: 3173-3184.
16. Smit MA, Peeper DS,. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) 2010; 2: 735-741.
17. Blain SW,. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008; 7: 892-898.
18. Nam EJ, Kim YT,. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 1169-1182.
19. Shapiro GI,. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783.
20. Yu Q, Sicinska E, Geng Y, et al., Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9: 23-32.
21. Hashiguchi Y, Tsuda H, Inoue T, et al., Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004; 35: 165-175.
22. Graf F, Mosch B, Koehler L, et al., Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging. Mini Rev Med Chem 2010; 10: 527-539.
23. Leonard JP, LaCasce AS, Smith MR, et al., Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-4607.
24. Dickson MA, Tap WD, Keohan ML, et al., Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024-2028.
25. Flaherty KT, Lorusso PM, Demichele A, et al., Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18: 568-576.
26. Anders L, Ke N, Hydbring P, et al., A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620-634.
27. Ruas M, Gregory F, Jones R, et al., CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms. Mol Cell Biol 2007; 27: 4273-4282.
28. Chandler H, Peters G,. Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol 2013.
29. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740.
30. Halasi M, Gartel AL,. Targeting FOXM1 in cancer. Biochem Pharmacol 2013; 85: 644-652.
31. Raychaudhuri P, Park HJ,. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
32. Gomes AR, Zhao F, Lam EW,. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chin J Cancer 2013; 32: 365-370.
33. Koo CY, Muir KW, Lam EW,. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28-37.
34. Yang C, Chen H, Tan G, et al., FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Lett 2013; 340: 104-112.
35. Ke Y, Zhao W, Xiong J, et al., miR-149 inhibits non-small-cell lung cancer Cells EMT by targeting FOXM1. Biochem Res Int 2013; 2013: 506731.
36. Balli D, Ustiyan V, Zhang Y, et al., Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J 2013; 32: 231-244.
37. Xu N, Jia D, Chen W, et al., FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One 2013; 8: e59412.